Tagraxofusp Clinical Trials

6 actively recruiting trials across 5 locations

Also known as: ELZONRIS, Elzonris, SL-401, SL-701, Elzonris, Tag

Pipeline

Phase 1: 2Phase 2: 2Phase 1/2: 2

Top Sponsors

Therapeutic Advances in Childhood Leukemia Consortium1
Stemline Therapeutics, Inc.1
Stanford University1
Karen Ballen, MD1
Joshua Zeidner1

Indications

Cancer6
Acute Myeloid Leukemia3
Blood Cancers1
Relapsed Acute Myeloid Leukemia1
Lymphoma, B-Cell1

Los Angeles, California2 trials

A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy

University of California, Los Angeles

Phase 2

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

Children's Hospital Los Angeles

Phase 1

Palo Alto, California1 trial

Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML

Stanford University

Phase 1/2

Miami, Florida1 trial

Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents

University of Miami

Phase 2

Boston, Massachusetts1 trial

A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax

Brigham and Women's Hospital

Phase 1/2

Philadelphia, Pennsylvania1 trial

Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002)

Thomas Jefferson University

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.